Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium

The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Parkinson's disease dementia (PDD). The meeting featured eight internationally known scientists from Europe and the United States and attracted over 200 scientists and physicians from academic centers, the National Institutes of Health, and the pharmaceutical industry. Methods for confirming and quantifying the presence of Lewy body and Alzheimer's pathology and novel biomarkers were discussed.

Citing Articles

Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer's disease.

Shantaraman A, Dammer E, Ugochukwu O, Duong D, Yin L, Carter E Mol Neurodegener. 2024; 19(1):60.

PMID: 39107789 PMC: 11302177. DOI: 10.1186/s13024-024-00749-1.

Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology.

Pillai J, Bena J, Tousi B, Rothenberg K, Keene C, Leverenz J Alzheimers Dement. 2024; 20(4):2564-2574.

PMID: 38353367 PMC: 11032524. DOI: 10.1002/alz.13704.

Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer's Disease.

Shantaraman A, Dammer E, Ugochukwu O, Duong D, Yin L, Carter E bioRxiv. 2024; .

PMID: 38328211 PMC: 10849701. DOI: 10.1101/2024.01.23.576728.

Protein Biomarkers Shared by Multiple Neurodegenerative Diseases Are Calmodulin-Binding Proteins Offering Novel and Potentially Universal Therapeutic Targets.

ODay D J Clin Med. 2023; 12(22).

PMID: 38002659 PMC: 10672630. DOI: 10.3390/jcm12227045.

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease.

Del Campo M, Vermunt L, Peeters C, Sieben A, Hok-A-Hin Y, Lleo A Nat Commun. 2023; 14(1):5635.

PMID: 37704597 PMC: 10499811. DOI: 10.1038/s41467-023-41122-y.

References

Lleo A, Cavedo E, Parnetti L, Vanderstichele H, Herukka S, Andreasen N . Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2014; 11(1):41-55. DOI: 10.1038/nrneurol.2014.232. View

Ferman T, Aoki N, Boeve B, Aakre J, Kantarci K, Graff-Radford J . Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution. Neurology. 2020; 95(2):e155-e165. PMC: 7455327. DOI: 10.1212/WNL.0000000000009763. View

Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler C . Does Parkinson's disease start in the gut?. Acta Neuropathol. 2017; 135(1):1-12. DOI: 10.1007/s00401-017-1777-8. View

Sutphen C, Jasielec M, Shah A, Macy E, Xiong C, Vlassenko A . Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015; 72(9):1029-42. PMC: 4570860. DOI: 10.1001/jamaneurol.2015.1285. View

Candelise N, Schmitz M, Llorens F, Villar-Pique A, Cramm M, Thom T . Seeding variability of different alpha synuclein strains in synucleinopathies. Ann Neurol. 2019; 85(5):691-703. DOI: 10.1002/ana.25446. View

Antelmi E, Pizza F, Donadio V, Filardi M, Sosero Y, Incensi A . Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients. Ann Clin Transl Neurol. 2019; 6(9):1872-1876. PMC: 6764627. DOI: 10.1002/acn3.50833. View

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

Schindler S, Bollinger J, Ovod V, Mawuenyega K, Li Y, Gordon B . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93(17):e1647-e1659. PMC: 6946467. DOI: 10.1212/WNL.0000000000008081. View

Manne S, Kondru N, Hepker M, Jin H, Anantharam V, Lewis M . Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders. J Neuroimmune Pharmacol. 2019; 14(3):423-435. PMC: 6669119. DOI: 10.1007/s11481-019-09835-4. View

10.

van Steenoven I, Koel-Simmelink M, Vergouw L, Tijms B, Piersma S, Pham T . Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Mol Neurodegener. 2020; 15(1):36. PMC: 7301448. DOI: 10.1186/s13024-020-00388-2. View

11.

Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C . Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol. 2016; 74(2):163-172. DOI: 10.1001/jamaneurol.2016.4547. View

12.

Goldman J, Forsberg L, Boeve B, Armstrong M, Irwin D, Ferman T . Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020; 12(1):137. PMC: 7597002. DOI: 10.1186/s13195-020-00703-5. View

13.

Wang Z, Becker K, Donadio V, Siedlak S, Yuan J, Rezaee M . Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020; . PMC: 7522783. DOI: 10.1001/jamaneurol.2020.3311. View

14.

Buchhave P, Minthon L, Zetterberg H, Wallin A, Blennow K, Hansson O . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012; 69(1):98-106. DOI: 10.1001/archgenpsychiatry.2011.155. View

15.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

16.

Howard E, Irwin D, Rascovsky K, Nevler N, Shellikeri S, Tropea T . Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. 2021; 96(14):e1855-e1864. PMC: 8105963. DOI: 10.1212/WNL.0000000000011699. View

17.

Irwin D, Fedler J, Coffey C, Caspell-Garcia C, Kang J, Simuni T . Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. Ann Neurol. 2020; 88(3):574-587. PMC: 7497251. DOI: 10.1002/ana.25811. View

18.

Zetterberg H, Skillback T, Mattsson N, Trojanowski J, Portelius E, Shaw L . Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurol. 2015; 73(1):60-7. PMC: 5624219. DOI: 10.1001/jamaneurol.2015.3037. View

19.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

20.

Mattsson-Carlgren N, Janelidze S, Bateman R, Smith R, Stomrud E, Serrano G . Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021; 13(6):e14022. PMC: 8185545. DOI: 10.15252/emmm.202114022. View